<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720406</url>
  </required_header>
  <id_info>
    <org_study_id>AssuitUniversity</org_study_id>
    <nct_id>NCT02720406</nct_id>
  </id_info>
  <brief_title>Topical Ketamine Analgesia in Children Undergoing Tonsillectomy: a Clinical and Serum Level Assays Study.</brief_title>
  <official_title>Topical Ketamine by Neubulization Method in Tonsillectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the analgesia efficacy of local ketamine given by two
      different doses in pediatric patients undergoing tonsillectomy operations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blinded, clinically-controlled trial, 100 child will be randomized into four
      groups of 25 patients each; control group, intravenous ketamine group received 0.5mg iv.
      ketamine, and two local ketamine groups receiving local ketamine by nebulization in two
      different doses; 1 and 2mg/kg. The verbal rating pain scale, time to first postoperative
      analgesic request, total analgesic consumption during 1st 24 h postoperative, serum ketamine
      levels, intra operative blood loss, postoperative bleeding, and adverse effects were
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesic consumption</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>The total amount of analgesics used in the first 24h postoperative in mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Pain intensity will be assessed postoperatively by using the Verbal Rating scale (VRS) (0 =no pain, 1 =mild pain, 2 =moderate pain, 3 =severe pain, and lastly 4 =excruciating pain). VRS assessments were performed at rest in the following time points; at arrival to PACU, 30 min, 1, 2, 3, 4, 5, 6, 12, and 24 h postoperative.
-
-
.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketamine serum levels to exclude systemic absorption of topical ketamine.</measure>
    <time_frame>120 min after receiving Ketamine</time_frame>
    <description>the level of ketamine in the serum.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Intravenous ketamine0.5mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulized ketamine 1mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulized ketamine 2mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group received placebo nebulization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ketamine0.5mg/kg</intervention_name>
    <description>Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.</description>
    <arm_group_label>Intravenous ketamine0.5mg/kg</arm_group_label>
    <other_name>Katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Ketamine 1mg/kg</intervention_name>
    <description>Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.</description>
    <arm_group_label>Nebulized ketamine 1mg/kg</arm_group_label>
    <other_name>Katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Ketamine 2mg/kg</intervention_name>
    <description>Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.</description>
    <arm_group_label>Nebulized ketamine 2mg/kg</arm_group_label>
    <other_name>Katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline placebo</intervention_name>
    <description>Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I-II patients aged 7-12 years and scheduled for elective
             tonsillectomy due to recurrent or chronic tonsillitis will be included in the study

        Exclusion Criteria:

          -  patients with known hypersensitivity to medication drugs, coagulation disorders,
             thrombocytopenia, and significant cardiac, renal, pulmonary or hepatic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant professor in anesthesia and intensive care, faculty of medicine, Assiut university, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <state>Assiut Governorate</state>
        <zip>Egypt,71571</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

